RemeGen strong growth, cash positive
RemeGen had a strong Q1 with 25% revenue growth, maintained gross margins despite price cuts, achieved operational cash flow positive for the first time, and closed a $650 million upfront payment from an out-licensing deal. The company expects strong domestic growth and pipeline delivery over the next 2-3 years, with improving margins and no need for additional financing.